15,419 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Bought by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 15,419 shares of the biotechnology company's stock, valued at approximately $2,123,000.

Other institutional investors also recently added to or reduced their stakes in the company. Rice Hall James & Associates LLC increased its position in Ascendis Pharma A/S by 2.0% during the 4th quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company's stock valued at $22,562,000 after purchasing an additional 3,274 shares during the period. abrdn plc boosted its holdings in shares of Ascendis Pharma A/S by 18.3% in the 4th quarter. abrdn plc now owns 187,180 shares of the biotechnology company's stock valued at $25,769,000 after buying an additional 28,967 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Ascendis Pharma A/S by 540.5% in the 4th quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company's stock valued at $76,000 after buying an additional 427 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in shares of Ascendis Pharma A/S by 14.0% in the 4th quarter. New York State Common Retirement Fund now owns 204,482 shares of the biotechnology company's stock valued at $28,151,000 after buying an additional 25,164 shares in the last quarter. Finally, Proficio Capital Partners LLC bought a new stake in shares of Ascendis Pharma A/S in the 4th quarter valued at about $1,725,000.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. The Goldman Sachs Group lifted their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Royal Bank of Canada lifted their target price on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Cantor Fitzgerald reiterated an "overweight" rating and issued a $200.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, May 12th. Morgan Stanley upgraded shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $180.00 to $250.00 in a research note on Monday, May 5th. Finally, Wedbush lifted their price objective on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $216.07.

Ascendis Pharma A/S Trading Up 0.0%

ASND traded up $0.06 during midday trading on Friday, hitting $157.60. The company's stock had a trading volume of 502,233 shares, compared to its average volume of 493,596. The firm has a market cap of $9.61 billion, a P/E ratio of -22.20 and a beta of 0.41. The firm has a 50-day moving average price of $157.15 and a two-hundred day moving average price of $142.64. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The business had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million. On average, equities analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.